ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
June 16, 2025
Company Presentation
Immunology
ImmuneOnco is a HK-listed (HK.1541), clinical stage biotech company focused on discovering and developing immunotherapies to treat cancer, immune diseases and other diseases.
Amulirafusp alfa (IMM0306) is a CD20xCD47 bispecific antibody with higher CD20 affinity, demonstrating strong ADCC, ADCP, and CDC activity.
Phase I monotherapy (up to 2.0 mg/kg QW) showed a favorable safety profile in lymphoma patients, with no DLTs observed.
In follicular lymphoma, combination with lenalidomide achieved 91% ORR and 27% CRR.
Early systemic lupus erythematosus (SLE) data (China study, n=8 at 0.8 mg/kg) showed rapid and sustained B-cell depletion immediately post-first dose.
Efficacy signals included significant improvements in SRI-4, SLEDAI-2000, BILAG-2004, proteinuria, anti-dsDNA, and PGA.
NMPA (China) has approved INDs for amulirafusp alfa in: SLE, lupus nephritis (LN) and neuromyelitis optica spectrum disorder (NMOSD).
Preference for licensing deals.
Company HQ City:
Shanghai
Company HQ State:
Shanghai
Company HQ Country:
China
Year Founded:
2015
Lead Product in Development:
Phase 3 SIRPa-Fc, the earliest readout in 2H2026
CEO
Dr. Wenzhi Tian
Development Phase of Lead Product
Phase III
Number of Unlicensed Products Looking for Licensing
5
Exchange
HongKong Stock Exchange
Ticker
1541.HK
When you expect your next catalyst update?
Results of IMM0306 in autoimmune disease (SLE) at BIO 2025
What is your next catalyst (value inflection) update?
June 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}